Targeting Claudin-1: A Novel Therapeutic Approach for Primary Sclerosing Cholangitis

Background and Disease Burden

Primary sclerosing cholangitis (PSC) is a chronic, progressive cholangiopathy characterized by inflammation and fibrosis of the bile ducts, ultimately leading to cholestasis, cirrhosis, and increased risk of hepatobiliary malignancies. Despite significant morbidity and the potential need for liver transplantation, the pathogenesis of PSC remains incompletely understood, and current therapeutic options are limited. The identification of novel mediators involved in PSC pathophysiology is critical for developing targeted therapies.

Study Design and Methods